Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study)

Centre Hospitalier Intercommunal Creteil

Status

Completed

Conditions

Constipation

Treatments

Dietary Supplement: L.reuteri

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03030664

BIOWELL

2016-A00419-42 (Other Identifier)

Details and patient eligibility

About

A randomized, multicenter, placebo-controlled, double blind study in two parallel groups testing the efficacy of daily oral supplementation with the probiotic L.reuteri DSM17938 compared to placebo in increasing the number of spontaneous bowel movements in infants and children with functional constipation.

Full description

Functional constipation in infants up to 4 years of age is defined according to Rome III criteria (Hyman 2006). The diagnose must include 1 month of at least two of the following criteria: two or fewer defecations per week; at least 1 episode per week of incontinence after the acquisition of toilet skills; history of excessive stool retention; history of painful or hard bowel movements; presence of a large faecal mass in the rectum; history of large-diameter stools that may obstruct the toilet.

Accompanying symptoms may include irritability, decreased appetite and/or early satiety. The accompanying symptoms disappear immediately following passage of a large stool.

There is a growing interest for the use of probiotics in functional constipation as research suggests that probiotics could provide beneficial support in the traditional treatment arsenal although the mechanisms of actions are not completely understood.

Wu et al have demonstrated that Lactobacillus reuteri DSM 17938 may have a region-specific intestinal effect on gut motility and therefore could be beneficial in treatment of constipation

Lactobacillus reuteri DSM 17938 has shown significant favourable effects in adults (Ojetti 2014) and young children as described above (Coccorullo 2010, Olgac 2013). These studies require confirmation however. The present clinical study has been designed to strengthen the current available data that L. reuteri DSM 17938 has beneficial effects in infants and young children with functional constipation.

We hypothesize that daily oral supplementation with the probiotic Lactobacillus reuteri DSM 17938 will effectively increase the number of spontaneous bowel movements in infants/children diagnosed with functional constipation according to Rome IV.

Enrollment

52 patients

Sex

All

Ages

6 months to 4 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age: 6 months up to 4 years
Suffering from functional constipation, as defined by modified Rome III criteria for children aged 4 years or less (Hyman 2006)
Parent(s) willingness to postpone major changes in the infant feeding mode
Parent(s) willingness and ability to fill in diary and questionnaires
Written informed consent from parents
Stated availability throughout the study period

Exclusion criteria

Chronic illness or major medical problem
Gastrointestinal disease (including organic cause of constipation and dyschezia or history of severe fecalome)
Intractable constipation (not responding to conventional treatment for more than 3 months)
Gastrointestinal surgery (in the year before enrolment)
Food allergy, lactose or gluten intolerance, as declared by parents
Use of L. reuteri two weeks before randomisation and throughout the intervention period. If fed with infant formula, it cannot contain L. reuteri.
Use of antibiotics two weeks before randomisation and throughout the intervention period, both infant/child and lactating mother
If breastfeeding, use of L reuteri by the mother 2 weeks prior to enrolment
Conventional treatment for constipation within 2 weeks before enrolment
Medication that influences gastrointestinal motility
Mental or behavioral disorders as judged by the investigator